Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

Six months into Donald Trump’s second term, his administration is at war with the federal judiciary, evading court orders ...

The U.S. health department is canceling or scaling back 22 BARDA-backed mRNA projects worth nearly $500 million, shifting ...

COVID-19 cases are on the rise nationwide, while Health Secretary Robert F. Kennedy Jr. has revoked mRNA vaccine research ...

Messenger RNA vaccines, or mRNA, differ from traditional ones. Instead of growing a virus and weakening it to allow the body to engage its natural defenses, mRNA vaccines use pieces of genetic code to ...

US Health Secretary Robert F. Kennedy Jr. has slashed government spending on mRNA vaccine research. Experts warn it will ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

Pediatrician Deborah Greenhouse writes that South Carolina is at risk because of the U.S. government’s decision to defund almost $500 million in mRNA vaccine research funding.